Puneet Varma (Editor)

Intercell

Updated on
Edit
Like
Comment
Share on FacebookTweet on TwitterShare on LinkedInShare on Reddit
Former type
  
Aktiengesellschaft

Fate
  
Merged with Vivalis SA

Defunct
  
2013 (2013)

Founded
  
1998

Ceased operations
  
2013

Industry
  
Biotechnology

Successor
  
Valneva SE

Headquarters
  
Vienna, Austria

Number of employees
  
410

Intercell httpsuploadwikimediaorgwikipediaenthumb8

Traded as
  
WBAG: ICLL OTCQX: INRLY

The fly on the wall morning market snapshot june 30 2010


Intercell AG was a biotechnology company based in Vienna which focused on the development of modern prophylactic and therapeutic vaccines against infectious diseases. Intercell was formed in 1998 as a spin-off of the Research Institute of Molecular Pathology (IMP) in Vienna. It employs 400 people in Austria, Scotland and the United States.

It has been listed on the Vienna Stock Exchange since February 28, 2005. In 2008, Intercell signaled its intent to acquire Maryland-based Iomai, a developer of needle-free vaccination technology.

Intercell cooperates with pharmaceutical companies like Novartis, Merck and Sanofi-Aventis on vaccine production.

The most important projects of Intercell are:

  • Vaccine against Japanese encephalitis (approved in Europe, America and Australia)
  • Therapeutic vaccine against hepatitis C (in clinical phase II)
  • Antigen identification program and adjuvant technologies.
  • Vaccine Enhancement Patch to improve prevention against pandemic influenza (in collaboration with U.S. Department of Health and Human Services, in clinical phase II)

    • References

    Intercell Wikipedia
    (Text) CC BY-SA